Alain Pluquet's Appointment

In bioMérieux’s Research and Development, Alain Pluquet’s key mission will be enhancing the company’s technology portfolio through in-house programs, external research partnerships and targeted technology acquisitions. His deep knowledge of the public research sector in France, and especially the CEA (French Atomic Energy Commission), will further strengthen bioMérieux’s ties with these institutions for a variety of joint research projects in the company’s technology strategy roadmap.

“bioMérieux’s number one priority is to help clinicians around the world improve patient care, by drastically reducing bacterial infection diagnostic time-to-results. We are creating this new Chief Technology Officer position to look at technologies that we have never contemplated before with the goal of bringing major innovation to public health”, stated Stéphane Bancel, Chief Executive Officer of bioMérieux. “We are very pleased to welcome Alain, whose experience, leadership and outside-the-box thinking will be invaluable as we reinvent our core technologies to build the diagnostic tools of the future.”

Alain Pluquet has a Ph.D. in nuclear physics from Fermilab in the U.S. and the CEA. He holds a Master degree in Fields-Particles-Matter from the French engineering school, Ecole Polytechnique and the University of Paris VI, VII, XI. Mr. Pluquet has worked in the CEA network since 1994. Before joining bioMérieux, he was Head of the Signal and Capturing Technology Department at the CEA LIST (Laboratory for system and technology integration).